Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
    • Subscribe
Advertisement

Optimizing CML Management: Shared Decision Making and Enhancing the Patient Experience : Episode 2

Opinion

Video

July 31, 2024

Navigating CML: Tools to Empower Patients and Caregivers

Author(s):

Jorge E. Cortes, MD,Joannie Clements

Joannie Clements, a patient advocate, provides insights on helping newly diagnosed patients with CML and their caregivers navigate the complexities of diagnosis, and Claire Saxton outlines resources available for them.

EP: 1.Understanding CML: Your Journey from Diagnosis to Treatment

Now Viewing

EP: 2.Navigating CML: Tools to Empower Patients and Caregivers

EP: 3.Empowering CML Caregivers: Strategies and Support Systems

EP: 4.Starting CML Treatment: Collaborative Choices for Better Outcomes

EP: 5.Open Dialogue in CML Care: Setting Expectations, Managing Side Effects, and Optimizing Patient Quality of Life

EP: 6.When CML Therapy Shifts: Collaborative Approaches to Treatment Changes

EP: 7.CML Treatment: Scenarios that Necessitate Switching Therapy

EP: 8.Ensuring Informed CML Care from Diagnosis Onward

EP: 9.Advancing CML Management Towards an Ideal Patient Journey

This program was made possible with support from Novartis Pharmaceuticals.

Video content above is prompted by the following questions:

  • As a patient advocate, how do you help newly diagnosed CML patients and their caregivers navigate the complexities of the diagnosis and set appropriate care goals? What are some of the biggest challenges patients may face at this stage?
  • What resources or educational materials have you found most helpful in supporting newly diagnosed CML patients and their caregivers?
    • How do patients typically use these materials? How have you changed your approaches so patients and caregivers can best leverage these materials?

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Illustration of doctor.
There was no evidence that CAR T directly caused secondary malignancies, despite FDA warnings, citing prior treatments as the cause, according to research.
Dr. Tycel Phillips is an Associate Professor in the Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, at City of Hope in Duarte, California.
Dr. Richard “Rick" Winneker
Related Content
Advertisement
Bispecific antibodies target specific cells, offering effective treatment for relapsed/refractory multiple myeloma, with varying side effect profiles: ©  stock.adobe.com
April 4th 2025

Understanding the Use of Bispecific Antibodies in Multiple Myeloma

Ryan Scott
Bispecific antibodies target specific cells, offering effective treatment for relapsed/refractory multiple myeloma, with varying side effect profiles.
Karen Cohn is a retired middle school special education teacher who was diagnosed with follicular lymphoma in July 2020. Catch up on all of Karen's blogs here!
March 31st 2025

The Positivity Trap of Follicular Lymphoma and Cancer

Karen Cohn
As a lymphoma survivor, I struggle with the positivity trap — sometimes, I just want my fears validated instead of being reassured everything is fine.
Itolizumab did not improve response rates at Day 29 in acute GVHD; however, the therapy showed significant benefits in long-term outcomes: © stock.adobe.com
March 27th 2025

Itolizumab Shows Long-Term Treatment Benefits in Acute GVHD

Ryan Scott
Although itolizumab did not improve response rates at Day 29 for patients with acute GVHD, the therapy showed significant benefits in long-term outcomes.
The first patients have been dosed in a trial of CAR T therapy in relapsed/refractory leukemia or lymphoma: © nobeatsoffierce - stock.adobe.com
March 22nd 2025

First Patients Dosed in WU-CART-007 Trial for Blood Cancer Subtypes

Alex Biese
The first patients have been dosed in a trial of CAR T therapy in relapsed/refractory T cell acute lymphoblastic leukemia or T cell lymphoblastic lymphoma.
FDA grants fast track designation to azer-cel in relapsed/refractory DLBCL: © stock.adobe.com
March 21st 2025

FDA Grants Fast Track Designation for Azer-Cel in Lymphoma Subset

Spencer Feldman
FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large B-cell lymphoma.
Darzalex and Revlimid maintenance improves survival following autologous stem cell transplantation in multiple myeloma: © stock.adobe.com.
March 18th 2025

Darzalex Plus Revlimid Improves Outcomes in Newly Diagnosed Myeloma

Alex Biese
Darzalex and Revlimid maintenance resulted in superior outcomes versus Revlimid alone following autologous stem cell transplantation in multiple myeloma.
Related Content
Advertisement
Bispecific antibodies target specific cells, offering effective treatment for relapsed/refractory multiple myeloma, with varying side effect profiles: ©  stock.adobe.com
April 4th 2025

Understanding the Use of Bispecific Antibodies in Multiple Myeloma

Ryan Scott
Bispecific antibodies target specific cells, offering effective treatment for relapsed/refractory multiple myeloma, with varying side effect profiles.
Karen Cohn is a retired middle school special education teacher who was diagnosed with follicular lymphoma in July 2020. Catch up on all of Karen's blogs here!
March 31st 2025

The Positivity Trap of Follicular Lymphoma and Cancer

Karen Cohn
As a lymphoma survivor, I struggle with the positivity trap — sometimes, I just want my fears validated instead of being reassured everything is fine.
Itolizumab did not improve response rates at Day 29 in acute GVHD; however, the therapy showed significant benefits in long-term outcomes: © stock.adobe.com
March 27th 2025

Itolizumab Shows Long-Term Treatment Benefits in Acute GVHD

Ryan Scott
Although itolizumab did not improve response rates at Day 29 for patients with acute GVHD, the therapy showed significant benefits in long-term outcomes.
The first patients have been dosed in a trial of CAR T therapy in relapsed/refractory leukemia or lymphoma: © nobeatsoffierce - stock.adobe.com
March 22nd 2025

First Patients Dosed in WU-CART-007 Trial for Blood Cancer Subtypes

Alex Biese
The first patients have been dosed in a trial of CAR T therapy in relapsed/refractory T cell acute lymphoblastic leukemia or T cell lymphoblastic lymphoma.
FDA grants fast track designation to azer-cel in relapsed/refractory DLBCL: © stock.adobe.com
March 21st 2025

FDA Grants Fast Track Designation for Azer-Cel in Lymphoma Subset

Spencer Feldman
FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large B-cell lymphoma.
Darzalex and Revlimid maintenance improves survival following autologous stem cell transplantation in multiple myeloma: © stock.adobe.com.
March 18th 2025

Darzalex Plus Revlimid Improves Outcomes in Newly Diagnosed Myeloma

Alex Biese
Darzalex and Revlimid maintenance resulted in superior outcomes versus Revlimid alone following autologous stem cell transplantation in multiple myeloma.
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.